Opinion
Video
Author(s):
Key opinion leaders examine patient response rates to biologic treatments and provide critical insights on transitioning between therapies to optimize patient outcomes.
Secukinumab Demonstrates Long-Term Safety and Efficacy in Pediatric Patients with GPP
The Cutaneous Connection: An Inside Look of the Inclusive Atlas
Psoriasis Resolution in a Patient Treated With CD19 CAR T-Cell Therapy for Refractory DLBCL
The Cutaneous Connection: Episode 31- Molecular Targeting of Psoriasis Biologics
Dermatology Times 2024 in Review: Psoriasis
Fighting the Flare of GPP: Expert Insights on Spesolimab